NASDAQ:HRTX - Heron Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Heron Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $21.00 -0.51 (-2.37 %) (As of 02/17/2020 04:00 PM ET) Add Compare Today's Range$20.81Now: $21.00▼$21.7150-Day Range$20.83MA: $22.31▼$24.5352-Week Range$15.68Now: $21.00▼$28.70Volume539,917 shsAverage Volume963,745 shsMarket Capitalization$1.89 billionP/E RatioN/ADividend YieldN/ABeta1.46 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HRTX Previous Symbol CUSIPN/A CIK818033 Webhttp://www.herontx.com/ Phone858-251-4400Debt Debt-to-Equity Ratio0.04 Current Ratio3.76 Quick Ratio3.51Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$77.47 million Price / Sales24.41 Cash FlowN/A Price / Cash FlowN/A Book Value$4.74 per share Price / Book4.43Profitability EPS (Most Recent Fiscal Year)($2.44) Net Income$-178,840,000.00 Net Margins-140.55% Return on Equity-60.76% Return on Assets-46.14%Miscellaneous Employees198 Outstanding Shares90,050,000Market Cap$1.89 billion Next Earnings Date2/28/2020 (Estimated) OptionableOptionable Receive HRTX News and Ratings via Email Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:HRTX Rates by TradingView Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions What is Heron Therapeutics' stock symbol? Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX." How were Heron Therapeutics' earnings last quarter? Heron Therapeutics Inc (NASDAQ:HRTX) issued its earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.15. The biotechnology company had revenue of $42.62 million for the quarter, compared to the consensus estimate of $34.02 million. Heron Therapeutics had a negative net margin of 140.55% and a negative return on equity of 60.76%. Heron Therapeutics's quarterly revenue was up 115.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.49) earnings per share. View Heron Therapeutics' Earnings History. When is Heron Therapeutics' next earnings date? Heron Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, February 28th 2020. View Earnings Estimates for Heron Therapeutics. What price target have analysts set for HRTX? 7 Wall Street analysts have issued 1 year target prices for Heron Therapeutics' shares. Their forecasts range from $32.00 to $75.00. On average, they expect Heron Therapeutics' stock price to reach $47.00 in the next twelve months. This suggests a possible upside of 123.8% from the stock's current price. View Analyst Price Targets for Heron Therapeutics. What is the consensus analysts' recommendation for Heron Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heron Therapeutics. What are Wall Street analysts saying about Heron Therapeutics stock? Here are some recent quotes from research analysts about Heron Therapeutics stock: 1. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (1/4/2020) 2. Evercore ISI analysts commented, "We remain highly constructive on the name as ‘011’s differentiated product profile and today’s opioid awareness environment should help propel adoption of the product in a wide range of surgical procedures. We’ve updated the model following earnings; PT remains $75 (OP). HRTX is confident that the answers to the FDA’s CRL are readily addressed. We will likely see a press release after the NDA is refiled, and the company plans to request a Type A meeting. The key dislocation: the company’s ‘011 timelines have reset, but the commercial opportunity remains unchanged. With the stock trading at these levels, we continue to see substantial upside if the company can execute its launch strategy." (8/13/2019) 3. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and $38 target price on HRTX shares after the company reported a nice sales beat driven by Cinvanti and provided a incremental update indicating it plans to meet with the FDA shortly" to discuss the responses to the CRL it received in May for HTX-011. We remain positive on HTX-011’s approvability as a local, non-opioid analgesic and given the low visibility into the company’s CRL resolution process, we think today’s update could suggest we are nearing a more material one on this front. We continue to view this as the company’s key upcoming catalyst." (8/5/2019) 4. Northland Securities analysts commented, "We believe these requirements are addressable, and anticipate resubmission prior to YE19, w/ approval in late-1H2020 or earlier. Heron Therapeutics reported 2Q results, with topline results beating expectations and EPS aligned with consensus. Product sales totaled $36.7MM, vs. our forecast of $32.3MM and the consensus of $31.8MM, respectively. Topline results reflected continued strength of CINVANTI, which posted sales of $33.2MM vs. our forecast of $28.5MM. CINVANTI sales advanced significantly sequentially from $28.0MM. SUSTOL sales were flat at $3.5MM, reflecting continued pressure from arbitrage relating to generic entry of palonestron. Importantly, Heron reiterated full-year product sales guidance of $115MM-to-$120MM. Operating loss and EPS were aligned with our expectations at ($51.8MM) and ($0.63), respectively." (8/5/2019) 5. Cowen Inc analysts commented, ": Post 1Q19, we are reiterating our Overweight rating and $18 PT on CHMA. We believe the stock continues to trade at a significant discount to its potential intrinsic value. We believe the risk-reward going into Phase 3 data for Mycapssa (oral octreotide) for the treatment of acromegaly, to be released in 3Q19, remains positive. As the company advances Mycapssa toward approval, we expect data readouts, approvals, and upward earnings revisions to drive CHMA’s stock higher." (5/9/2019) Has Heron Therapeutics been receiving favorable news coverage? News coverage about HRTX stock has trended somewhat negative this week, according to InfoTrie. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Heron Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Heron Therapeutics. Who are some of Heron Therapeutics' key competitors? Some companies that are related to Heron Therapeutics include Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Horizon Therapeutics (HZNP), Amarin (AMRN), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Evotec (EVTCY), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), FibroGen (FGEN) and GW Pharmaceuticals PLC- (GWPH). What other stocks do shareholders of Heron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include bluebird bio (BLUE), Immunomedics (IMMU), Cara Therapeutics (CARA), Amarin (AMRN), Gilead Sciences (GILD), Micron Technology (MU), Seattle Genetics (SGEN), Pfizer (PFE), Progenics Pharmaceuticals (PGNX) and Alibaba Group (BABA). Who are Heron Therapeutics' key executives? Heron Therapeutics' management team includes the folowing people: Dr. Barry D. Quart, Pres, CEO & Director (Age 62)Mr. Robert E. Hoffman C.P.A., CPA, CFO & Sr. VP of Fin. (Age 53)Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 59)Mr. David L. Szekeres, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 45)Mr. Sean T. Ristine, VP of HR (Age 49) Who are Heron Therapeutics' major shareholders? Heron Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (13.73%), FMR LLC (7.31%), Tang Capital Management LLC (5.57%), ArrowMark Colorado Holdings LLC (4.56%), State Street Corp (3.75%) and FIL Ltd (2.42%). Company insiders that own Heron Therapeutics stock include Barry D Quart, John Poyhonen, Kevin C Tang, Kimberly Manhard, Robert Hoffman, Robert Rosen and Waage Christian. View Institutional Ownership Trends for Heron Therapeutics. Which major investors are selling Heron Therapeutics stock? HRTX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bridger Management LLC, Tang Capital Management LLC, Candriam Luxembourg S.C.A., Sofinnova Investments Inc., UBS Group AG, Broadfin Capital LLC and Panagora Asset Management Inc.. View Insider Buying and Selling for Heron Therapeutics. Which major investors are buying Heron Therapeutics stock? HRTX stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Farallon Capital Management LLC, Goldman Sachs Group Inc., State Street Corp, Artisan Partners Limited Partnership, FIL Ltd, Tang Kevin C and Renaissance Technologies LLC. Company insiders that have bought Heron Therapeutics stock in the last two years include Barry D Quart, John Poyhonen, Kevin C Tang and Waage Christian. View Insider Buying and Selling for Heron Therapeutics. How do I buy shares of Heron Therapeutics? Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Heron Therapeutics' stock price today? One share of HRTX stock can currently be purchased for approximately $21.00. How big of a company is Heron Therapeutics? Heron Therapeutics has a market capitalization of $1.89 billion and generates $77.47 million in revenue each year. The biotechnology company earns $-178,840,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Heron Therapeutics employs 198 workers across the globe.View Additional Information About Heron Therapeutics. What is Heron Therapeutics' official website? The official website for Heron Therapeutics is http://www.herontx.com/. How can I contact Heron Therapeutics? Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected] MarketBeat Community Rating for Heron Therapeutics (NASDAQ HRTX)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 594 (Vote Outperform)Underperform Votes: 483 (Vote Underperform)Total Votes: 1,077MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe HRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2020 by MarketBeat.com StaffFeatured Article: What is a back-end load?
